Nature Medicine, Published online: 19 October 2025; doi:10.1038/s41591-025-04029-3
As presented at the European Society for Medical Oncology Congress 2025: In patients with locally advanced or metastatic solid tumours, including mesothelioma, treatment with a first-in-class inhibitor of the Hippo−YAP−TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma.
